Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cellectar Biosciences Inc

CLRB
Current price
2.67 USD -0.23 USD (-7.93%)
Last closed 2.9 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 95 716 568 USD
Yield for 12 month +30.88 %
1Y
3Y
5Y
10Y
15Y
CLRB
21.11.2021 - 28.11.2021

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

12.6 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+330 366 USD

Current Year

-192 375 USD

Last Year

-238 867 USD

Current Quarter

-88 490 USD

Last Quarter

+260 406 USD

Key Figures CLRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -42 018 520 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -91.47 %
PEG Ratio
Return On Equity TTM -304.38 %
Wall Street Target Price 12.6 USD
Revenue TTM
Book Value 0.27 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -3.09 USD
Diluted Eps TTM -3.09 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CLRB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CLRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 22.07.2022
Dividend Date 17.07.2018

Stock Valuation CLRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -2.8446
Price Book MRQ 2.6673

Financials CLRB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CLRB

For 52 weeks

1.56 USD 4.45 USD
50 Day MA 3.19 USD
Shares Short Prior Month 2 271 661
200 Day MA 3.02 USD
Short Ratio 2.9
Shares Short 2 173 268
Short Percent 7.19 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds


S

SLICHA

203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics

Metals


Gold

2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics